HL-07 is under clinical development by Huons Global and currently in Phase I for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase I drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HL-07’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HL-07 overview
HL-07 is under development for the treatment of dry eye syndrome. The drug candidate is developed based on gene recombinant production technology using E. coli fermentation. It is based on recombinant protein thymosin beta 4 (TB4) peptide. TB4 is a synthetic version of a naturally occurring peptide.
Huons Global overview
Huons Global (Huons) is a pharmaceutical company that provides medical solutions for human health. The company carries out development, manufacture and distribution of pharmaceutical products and medical devices. Its product portfolio includes a wide range of ethical drugs, over the counter drugs, healthcare foods and medical devices. Huons offers its products in various formulations such as capsules, tablets, vials, suspensions, syrup, injections and eye drops. It also offers custom manufacturing services to manufacture a wide variety of pharmaceutical products. It markets its products in the markets of Latin America, the US, Asia, Middle East, Africa, and Europe. Huons is headquartered in Seongnam, Gyeonggi, South Korea .
For a complete picture of HL-07’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - HL-07 in Keratoconjunctivitis Sicca (Dry Eye)
Premium Insights
The gold standard of business intelligence.
